Related Experiment Videos
Susceptibility of methicillin-resistant Staphylococcus aureus to minocycline and other antimicrobials
1King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Abstract:
The incidence of methicillin-resistant Staphylococcus aureus (MRSA) is on the rise, especially in nosocomial and intravenous-drug-abuse-related infections, with a concomitant increase in morbidity, mortality and health care costs. At present the drug of choice, vancomycin, which must be administered intravenously, is expensive and can cause serious side effects in vancomycin-intolerant patients. Recently, minocycline has received much attention as an antibiotic to combat the increasing frequency of MRSA-related infections. We tested 102 recent clinical isolates of MRSA from tertiary-care patients and found none to be resistant to minocycline, with minimum inhibitory concentrations of < 1-2 micrograms/ml. The only other drug that inhibited all the strains was vancomycin, followed by ciprofloxacin (87%), clindamycin (55%) and chloramphenicol (52%). Gentamicin, beta-lactams, tetracycline and trimethoprim-sulfamethoxazole had little or no activity against our isolates of MRSA.
Insights
Minocycline shows promise in combating rising methicillin-resistant Staphylococcus aureus (MRSA) infections. This study found no MRSA strains resistant to minocycline, suggesting its potential as an effective treatment option.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Rising incidence of methicillin-resistant Staphylococcus aureus (MRSA) infections, particularly in healthcare settings and among intravenous drug users.
- Increasing morbidity, mortality, and healthcare costs associated with MRSA infections.
- Limitations of current first-line treatments like vancomycin, including high cost, intravenous administration, and potential side effects.
Purpose of the Study:
- To evaluate the efficacy of minocycline against recent clinical isolates of MRSA.
- To compare minocycline's activity with other commonly used antibiotics against MRSA.
Main Methods:
- Testing of 102 clinical MRSA isolates from tertiary-care patients.
- Determination of minimum inhibitory concentrations (MICs) for minocycline and other antibiotics.
- Comparative analysis of antibiotic susceptibility profiles.
Main Results:
- No tested MRSA isolates exhibited resistance to minocycline, with MICs ranging from < 1-2 µg/ml.
- Vancomycin was the only other antibiotic that inhibited all MRSA strains.
- Significant variations in activity were observed for other antibiotics: ciprofloxacin (87%), clindamycin (55%), chloramphenicol (52%), with limited activity from gentamicin, beta-lactams, tetracycline, and trimethoprim-sulfamethoxazole.
Conclusions:
- Minocycline demonstrates potent in vitro activity against contemporary MRSA clinical isolates.
- Minocycline represents a potential therapeutic alternative for MRSA infections, especially considering vancomycin's limitations.
- Further clinical investigation is warranted to establish minocycline's role in MRSA treatment.